Preservation of recall immunity in anti-CD3-treated recent onset type 1 diabetes patients.
BACKGROUND: The safety of any immune modulating agent in type 1 diabetes mellitus (T1DM) involves its selectivity on autoimmunity and its preservation of recall and tumour immunity. METHODS: We performed lymphocyte proliferation tests on seven recent onset diabetic patients treated with anti-CD3 (O...
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Conference item |
| Published: |
2011
|